Phospho-RPS6KA5 (S360) Antibody

What is RPS6KA5 and what cellular function does its phosphorylation at S360 indicate?

RPS6KA5 (also known as MSK1) is a 90 kDa ribosomal protein S6 kinase that functions as a serine/threonine protein kinase essential for regulating various cellular processes. It is required for mitogen or stress-induced phosphorylation of transcription factors CREB1 and ATF1 and contributes to gene activation through histone phosphorylation . Phosphorylation at Serine 360 is a critical regulatory event that occurs in response to mitogenic or stress stimuli such as UV-C irradiation, epidermal growth factor (EGF), and anisomycin treatment . This specific phosphorylation is considered an activation marker of MSK1 and indicates active signaling through the MAPK/ERK pathway.

How does Phospho-RPS6KA5 (S360) differ from other phosphorylation sites on MSK1?

MSK1 contains multiple phosphorylation sites including S360 and S376, each with distinct roles in regulating its kinase activity. While S360 phosphorylation is primarily associated with the activation of the N-terminal kinase domain, S376 phosphorylation (often detected by antibodies like those described in search result ) is associated with the C-terminal kinase domain activation . The S360 phosphorylation site is particularly important as a marker of MSK1 activation in response to mitogenic signals and cellular stress, while other sites may be involved in different regulatory mechanisms. When designing experiments, researchers should carefully select the appropriate phospho-specific antibody based on which activation pathway they are investigating.

What is the molecular weight expected for RPS6KA5 in Western blot applications?

When working with RPS6KA5 antibodies for Western blot applications, researchers should expect to observe a band at approximately 111 kDa, though the calculated molecular weight is around 89.865 kDa . This discrepancy is common with many phosphorylated proteins due to post-translational modifications that can affect protein migration during electrophoresis. It's important to note this difference when validating antibody specificity and interpreting Western blot results to avoid misidentification of the target protein.

How does the phosphorylation state of RPS6KA5 at S360 correlate with activation of downstream transcription factors?

The phosphorylation of RPS6KA5/MSK1 at S360 directly correlates with its ability to phosphorylate downstream transcription factors including CREB1, ATF1, and RELA (p65 NF-κB) . Research indicates that S360 phosphorylation is a prerequisite for the N-terminal kinase domain activation, which is responsible for phosphorylating these transcription factors. In EGF-stimulated cells, phospho-S360-MSK1 shows nuclear localization and colocalizes with phosphorylated transcription factors, demonstrating the spatial relationship between MSK1 activation and downstream signaling .

For quantitative assessment of this correlation, researchers can employ dual immunofluorescence staining to simultaneously detect phospho-S360-MSK1 and phosphorylated transcription factors (e.g., phospho-CREB) following cell stimulation. Studies have shown that inhibiting S360 phosphorylation via specific kinase inhibitors results in proportional decreases in CREB and histone H3 phosphorylation, further confirming this functional relationship.

What are the differences in RPS6KA5 (S360) phosphorylation patterns between acute stress response and chronic inflammatory conditions?

Acute stress responses (such as UV irradiation or brief exposure to inflammatory cytokines) typically result in rapid and transient phosphorylation of RPS6KA5 at S360, peaking at 15-30 minutes post-stimulation and declining within 2 hours . In contrast, chronic inflammatory conditions are characterized by sustained but often lower-intensity phosphorylation of S360, accompanied by changes in MSK1 subcellular localization.

In experimental models of chronic inflammation, researchers have observed that while the acute phase shows nuclear accumulation of phospho-S360-MSK1, prolonged inflammatory signaling can lead to cytoplasmic retention and altered substrate specificity. This differential phosphorylation pattern has significant implications for drug development targeting inflammatory disorders, as compounds designed to modulate MSK1 activity may need to account for these temporal phosphorylation dynamics.

How does cross-reactivity between MSK1 and MSK2 affect the interpretation of phospho-S360 antibody results?

MSK1 (RPS6KA5) and MSK2 (RPS6KA4) share significant sequence homology, particularly around key phosphorylation sites. Some commercial antibodies detect both MSK1 phosphorylated at S360 and MSK2 phosphorylated at the equivalent position (S343) . This cross-reactivity can complicate data interpretation, especially in cell types that express both isoforms.

To address this challenge, researchers should:

• Conduct validation experiments using MSK1 and MSK2 knockout cell lines to determine antibody specificity

• Consider using confirming techniques such as immunoprecipitation followed by mass spectrometry

• Incorporate siRNA-mediated knockdown of each isoform to distinguish their relative contributions to observed signals

Data from comparative studies suggest that while both kinases can be phosphorylated at the homologous sites, their regulation and downstream targets may differ in a cell type and stimulus-specific manner, making accurate discrimination between these isoforms essential for mechanistic studies.

What are the optimal conditions for detecting phospho-RPS6KA5 (S360) in different experimental systems?

Optimal detection of phospho-RPS6KA5 (S360) requires careful attention to experimental conditions that preserve the phosphorylation state while providing sufficient specificity. The following table summarizes optimal conditions for different experimental applications:

For optimal results when stimulating cells to induce phosphorylation, treatments with EGF (200 ng/mL) or PMA have been demonstrated to effectively increase phospho-S360 levels in HeLa cells, with maximum phosphorylation typically observed between 15-30 minutes post-stimulation .

How should researchers validate the specificity of phospho-RPS6KA5 (S360) antibodies?

Validating phospho-specific antibodies is essential for generating reliable research data. A comprehensive validation protocol for phospho-RPS6KA5 (S360) antibodies should include:

• Phosphatase treatment control: Treating one sample with lambda phosphatase to remove phosphorylation should eliminate signal from a truly phospho-specific antibody

• Stimulation-inhibition paradigm: Compare signals from unstimulated cells, cells stimulated with activators known to induce S360 phosphorylation (e.g., EGF, PMA), and stimulated cells pre-treated with specific inhibitors of upstream kinases (e.g., U0126 for MEK/ERK pathway)

• Peptide competition assay: Pre-incubation of the antibody with the phosphorylated peptide immunogen should abolish specific signal

• Genetic verification: Using CRISPR/Cas9-generated S360A mutant cell lines where the serine is replaced by alanine, preventing phosphorylation at this site

• Cross-validation: Compare results using multiple phospho-S360 antibodies from different manufacturers or different clones

Researchers should document these validation steps in their methodology sections to strengthen the credibility of their findings regarding RPS6KA5 phosphorylation.

What controls should be included when studying RPS6KA5 (S360) phosphorylation dynamics?

For rigorous experimental design when studying RPS6KA5 (S360) phosphorylation dynamics, the following controls are recommended:

• Total RPS6KA5 measurement: Always pair phospho-specific detection with assessment of total RPS6KA5 protein levels to normalize phosphorylation signals and account for expression differences

• Positive control: Include cells treated with established activators (e.g., EGF at 200 ng/mL for 15-30 minutes as described in search result )

• Negative control: Include samples treated with specific inhibitors of upstream pathways (MEK inhibitors U0126 or PD98059)

• Time course analysis: For signaling dynamics studies, include multiple time points (0, 5, 15, 30, 60, 120 minutes) after stimulation

• Loading control: Include detection of housekeeping proteins or total protein measurement (Ponceau S staining) for normalization

• Antibody control: When possible, include isotype control antibodies and phospho-null (S360A) mutant samples

These controls collectively strengthen the interpretation of phosphorylation data and allow for more accurate quantification of signaling dynamics.

Why might there be discrepancies between observed and expected molecular weight for phospho-RPS6KA5?

Several factors can contribute to discrepancies between the observed molecular weight (approximately 111 kDa) and the calculated molecular weight (89.865 kDa) for RPS6KA5 :

• Post-translational modifications: Multiple phosphorylation events on RPS6KA5 can significantly affect gel migration, typically increasing apparent molecular weight

• Isoform expression: Different splice variants of RPS6KA5 may be expressed in different cell types, affecting molecular weight

• Sample preparation conditions: Insufficient denaturation or reduction can result in altered migration patterns

• Gel percentage and buffer system: The percentage of acrylamide and buffer composition can influence protein migration

To address these discrepancies, researchers should:

• Use protein ladders with appropriate molecular weight ranges

• Compare observed bands with those from well-characterized positive control samples

• Consider using gradient gels (4-20%) for better resolution

• Confirm protein identity using mass spectrometry when possible

• Always report both observed and expected molecular weights in publications

How can researchers troubleshoot weak or absent phospho-RPS6KA5 (S360) signal in stimulated samples?

When facing challenges with weak or absent phospho-RPS6KA5 (S360) signal despite stimulation, consider the following troubleshooting approaches:

• Phosphatase activity: Ensure phosphatase inhibitors are fresh, used at appropriate concentrations, and added immediately during sample collection

• Stimulation efficiency: Verify that the stimulation actually activated the upstream pathways by checking phosphorylation of ERK1/2 as a positive control

• Antibody quality: Antibody may have deteriorated; perform dot blot with phospho-peptide immunogen to check antibody reactivity

• Signal timing: RPS6KA5 phosphorylation is often transient; perform a detailed time course to ensure sample collection at peak phosphorylation

• Cell type variations: Different cell types may have different optimal stimulation conditions; adjust concentrations and timing accordingly

• Sample handling: Minimize time between cell lysis and protein denaturation; keep samples cold and process rapidly

• Detection method sensitivity: Consider using enhanced chemiluminescence substrates with higher sensitivity or switching to fluorescent detection systems

Systematic investigation of these factors often resolves detection issues for phospho-RPS6KA5 (S360).

How can phospho-RPS6KA5 (S360) antibodies be utilized to study the crosstalk between MAPK and NF-κB signaling pathways?

Phospho-RPS6KA5 (S360) antibodies offer valuable tools for investigating the crosstalk between MAPK and NF-κB signaling pathways, as RPS6KA5/MSK1 represents a critical node connecting these pathways . Methodological approaches include:

• Sequential immunoprecipitation: Use phospho-S360 antibodies to immunoprecipitate active MSK1, followed by analysis of co-precipitating proteins from both pathways

• Chromatin immunoprecipitation (ChIP): Employ phospho-S360 antibodies in ChIP assays to identify genomic loci where activated MSK1 is recruited, correlating with activation of specific NF-κB or MAPK-dependent genes

• Proximity ligation assay (PLA): Combine phospho-S360 antibodies with antibodies against NF-κB components to visualize and quantify their physical interaction in situ

• Pharmacological dissection: Use selective inhibitors of each pathway while monitoring phospho-S360-MSK1 levels to determine hierarchical relationships

• Multiplexed phosphoproteomic analysis: Couple phospho-S360 immunoprecipitation with mass spectrometry to identify additional phosphorylation events on interacting proteins

These approaches have revealed that in TNF-α stimulated cells, MSK1 phosphorylation at S360 occurs via the MAPK pathway but influences subsequent NF-κB signaling through phosphorylation of p65 at Ser276, demonstrating how these antibodies can illuminate complex signaling networks.

What are the methodological considerations for using phospho-RPS6KA5 (S360) antibodies in neuroscience research?

Neuroscience research presents unique challenges and opportunities for utilizing phospho-RPS6KA5 (S360) antibodies, given MSK1's importance in neuronal plasticity and response to neurotrophic factors. Key methodological considerations include:

• Tissue-specific optimization: Brain tissue contains high levels of phosphatases; use stronger phosphatase inhibitor cocktails and minimize post-mortem interval for tissue collection

• Neuronal subcellular localization: Consider using subcellular fractionation to separate nuclear, cytoplasmic, synaptosomal, and dendritic fractions before immunoblotting

• Activity-dependent phosphorylation: In neuronal cultures or brain slices, synchronize neuronal activity (using KCl, BDNF, or electrical stimulation) before fixation/lysis to capture activity-dependent phosphorylation events

• Co-localization with neuronal markers: In immunohistochemistry, pair phospho-S360 antibodies with neuronal subtype markers to identify specific neuronal populations exhibiting MSK1 activation

• Compatibility with stereotaxic techniques: For in vivo studies, validate antibody compatibility with fixation methods commonly used after stereotaxic injections or optogenetic stimulation

• Developmental considerations: MSK1 expression and phosphorylation patterns change during development; adjust extraction and detection protocols accordingly

These specialized approaches have enabled researchers to demonstrate MSK1's critical role in BDNF-induced CREB phosphorylation in neurons and its involvement in learning and memory processes through histone H3 phosphorylation.

How can phospho-RPS6KA5 (S360) antibodies contribute to cancer research and potential therapeutic development?

Phospho-RPS6KA5 (S360) antibodies have significant applications in cancer research and drug development, particularly given MSK1's role in cell proliferation and stress response pathways commonly dysregulated in cancer:

• Biomarker development: Phospho-S360-MSK1 levels can serve as biomarkers for MAPK pathway activation in tumor samples, potentially predicting responsiveness to RAF/MEK inhibitors

• Target engagement studies: These antibodies can confirm on-target activity of MSK1 inhibitors by demonstrating reduced S360 phosphorylation in dose-response studies

• Resistance mechanism investigation: In cancer cells developing resistance to MAPK pathway inhibitors, monitoring phospho-S360-MSK1 can reveal pathway reactivation or compensatory signaling

• Patient-derived xenograft (PDX) models: Comparing phospho-S360-MSK1 levels between patient tumors and corresponding PDX models can validate model fidelity for drug testing

• Immunohistochemical profiling: Using phospho-S360 antibodies on tissue microarrays allows correlation of MSK1 activation with clinical outcomes across large patient cohorts

Studies using these approaches have identified elevated phospho-S360-MSK1 levels in certain breast and prostate cancer subtypes , and demonstrated that targeted inhibition of MSK1 can potentiate the effects of conventional chemotherapeutics in preclinical models.

What emerging technologies are enhancing the utility of phospho-RPS6KA5 (S360) antibodies in basic and translational research?

Recent technological advancements are expanding the applications of phospho-RPS6KA5 (S360) antibodies beyond traditional biochemical assays:

• Single-cell phosphoproteomic analysis: Integration of phospho-S360 antibodies with mass cytometry (CyTOF) or single-cell Western blotting allows assessment of MSK1 activation heterogeneity within cell populations

• Spatially-resolved phosphoproteomic imaging: Combining phospho-S360 antibodies with technologies like Nanostring GeoMx or 10X Visium enables spatial mapping of MSK1 activation within tissue architecture

• Live-cell phosphorylation sensors: Development of FRET-based biosensors incorporating phospho-specific nanobodies derived from phospho-S360 antibodies allows real-time monitoring of MSK1 activation dynamics

• Phosphoproteomic profiling: Deep phosphoproteomic analysis before and after MSK1 activation provides comprehensive understanding of downstream signaling networks

• Structural biology applications: Phospho-S360 antibodies can be used to stabilize specific MSK1 conformations for cryo-EM structural studies

These emerging approaches promise to further elucidate the complex role of MSK1 phosphorylation in normal physiology and disease, potentially identifying new therapeutic opportunities targeting this signaling node.